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Clinical drug effectsBackground: Drug repositioning is the process of finding new indications for existing drugs. Its impor-
tance has been dramatically increasing recently due to the enormous increase in new drug discovery cost.
However, most of the previous molecular-centered drug repositioning work is not able to reflect the
end-point physiological activities of drugs because of the inherent complexity of human physiological
systems.
Methods: Here, we suggest a novel computational framework to make inferences for alternative indica-
tions of marketed drugs by using electronic clinical information which reflects the end-point physiolog-
ical results of drug’s effects on the biological activities of humans. In this work, we use the concept of
complementarity between clinical disease signatures and clinical drug effects. With this framework,
we establish disease-related clinical variable vectors (clinical disease signature vectors) and
drug-related clinical variable vectors (clinical drug effect vectors) by applying two methodologies (i.e.,
statistical analysis and literature mining). Finally, we assign a repositioning possibility score to each dis-
ease–drug pair by the calculation of complementarity (anti-correlation) and association between clinical
states (‘‘up” or ‘‘down”) of disease signatures and clinical effects (‘‘up”, ‘‘down” or ‘‘association”) of drugs.
A total of 717 clinical variables in the electronic clinical dataset (NHANES), are considered in this study.
Results: The statistical significance of our prediction results is supported through two benchmark data-
sets (Comparative Toxicogenomics Database and Clinical Trials). We discovered not only lots of known
relationships between diseases and drugs, but also many hidden disease–drug relationships. For example,
glutathione and edetic-acid may be investigated as candidate drugs for asthma treatment. We examined
prediction results by using statistical experiments (enrichment verification, hyper-geometric and permu-
tation test P < 0.009 in Comparative Toxicogenomics Database and Clinical Trials) and presented
evidences for those with already published literature.
Conclusion: The results show that electronic clinical information is a feasible data resource and utilizing
the complementarity (anti-correlated relationships) between clinical signatures of disease and clinical
effects of drugs is a potentially predictive concept in drug repositioning research. It makes the proposed
approach useful to identity novel relationships between diseases and drugs that have a high probability
of being biologically valid.
 2015 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug repositioning is defined as the process of finding new uses
outside the scope of the original medical indications for existing
drugs. Its importance has been dramatically increasing recentlydue to the enormous increase in new drug discovery cost [1,2].
Because 90% of new drug candidates fail in early tests of safety
and efficacy in de novo drug discovery, many researchers are apply-
ing repositioning strategies to discover novel therapeutics of
known drugs.
Drug and target protein characteristics based on chemical struc-
tures and the properties of ligands and receptors have been used to
identify new targets for existing drugs. Keiser et al. make use of
chemical similarities between drugs [3]. The Keiser hypothesis
was that structurally similar chemicals tend to have similar prop-
erties. In other words, similar molecules exhibit similar biological
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physical interactions between drugs and targets, which is called
docking method [4–6]. Their methods for drug repositioning
assume that a chemical would be a feasible candidate for a treat-
ment of a disease when the chemical physically binds to the target
protein of interest, which has already been reported to play an
important role in development or treatment of the disease. Bleak-
ley et al., Mei et al., and van Laarhoveb et al. take into account uni-
fied resources including chemical structures, amino-acid
sequences of target proteins, and chemical–protein interaction
network [7–9]. Even though these approaches can be considered
as systematic and comprehensive means to find new molecular
targets for existing drugs, there are some drawbacks for finding
new uses of known drugs. Their primary limitation is an inconsis-
tency between the results from these methods and clinical thera-
peutic effects. Additionally, in physical binding simulations
between drugs and its targets, three-dimensional-structure
libraries of both chemical compounds and target proteins are
required. Unfortunately, 3D libraries of both chemical compounds
and proteins have not been completely identified so far. Although
information about 3D structure can be inferred from 2D structure,
this may also introduce errors that may occur in the
transformation.
Gene expression information is also widely used for drug repo-
sitioning [10–12]. Several studies have tried to identify novel uses
of existing drugs by analyzing patterns of gene expression-
signatures of both drug-associated and disease-associated gene
sets. Although those studies have suggested computational
approaches to discover new drug indications by taking experimen-
tal outcomes of molecular activity into account, there are still
problems that make some improvements necessary. First is the
gap of chemical responses between molecular and phenotypic
levels of the entire human system. For instance, in complex phys-
iological systems, it may be hard to represent the overall molecular
responses of chemicals with only gene expression data because
gene expression profiles are derived from separated-cell lines trea-
ted with each chemical. Secondly, the experimental process
requires enormous time and cost to retain enough expression data
to use in research.
Clinical information may provide new opportunities to directly
connect chemicals to clinical therapeutic effects in complex phys-
iological systems because clinical information not only indicates
the phenotypic states of disease-conditions, but also reflects the
end-physiological results of chemical impacts on human biological
activity [13,14].
One of the strategies for drug repositioning with clinical infor-
mation is the side-effects-based approach [15,16]. In these studies,
an underlying assumption was that if many side-effects are shared
between drugs having different indications, then the drugs could
be repositioned.
Recently, many researchers in biomedical fields have focused on
another resource of the electronic clinical data [17–19]. Electronic
clinical information encompasses a variety of medical histories,
such as diagnoses, prescriptions, and laboratory test results, and
they are accumulated when medical services are provided to
patients in medical institutions. With the rapid increase in the
adoption of the electronic clinical information systems, there is
now plenty of clinical data, which provides a promising opportu-
nity to investigate hidden connections between diseases and clin-
ical variables [20]. In addition, most doctors prescribe medicines
based on the clinical status or symptoms of patients. Therefore,
electronic clinical information can directly help identify alternative
indications of already approved drugs.
One potential source in electronic clinical information for drug
repositioning is the free text in the clinical notes that has explicit
information about disease–drug relationships [21–23]. The basicidea of the study is to count the number of times that a disease
and a drug co-occur in the same free text and compare that count
to the number of expected co-occurrences by chance. This
approach can be used easily, but it may lead to many false-
positives. Moreover, it does not consider other useful structured
data for drug repositioning included in the electronic clinical data,
such as laboratory test and medical survey results that can capture
clinical disease signatures.
Here, we suggest a systematic framework (Fig. 1) to make infer-
ences for new uses of known drugs using the structured data in the
electronic clinical information. The electronic clinical information
was from National Health and Nutrition Examination Survey
(NHANES) which was provide by National Center for Health Statis-
tics (NCHS) in the USA [24]. We adopted the clinical-level comple-
mentarity between clinical disease signatures and drug effects. In
this framework, we established clinical variable vectors for dis-
eases and drugs by applying two methodologies (statistical analy-
sis on electronic clinical information and literature mining on
PubMed). Then, we assigned a score to each disease–drug pair
based on both complementarity and association between clinical
variable vectors for diseases and drugs. We validated our predic-
tion results by making use of two independent datasets, Compara-
tive Toxicogenomics Database (CTD) [25] and Clinical Trials [26].
CTD is a database containing chemical-disease, chemical-gene
and gene-disease interactions manually curated from literature,
and Clinical Trials is a database for clinical studies of human partic-
ipants in 190 countries (http://clinicaltrials.gov/).
The statistical significance of our prediction results is supported
through two benchmark datasets (enrichment verification, hyper-
geometric, and permutation test P < 0.009 in CTD and Clinical Tri-
als). Through our prediction results, we discovered that glu-
tathione and edetic-acid may be investigated as candidate drugs
for asthma treatment. These results show that using electronic
clinical information and the concept of clinical-level complemen-
tarity can offer promising insights into drug repositioning research.2. Materials and preprocessing
2.1. Data sources
We obtained electronic clinical information from the cross-
sectional epidemiological database called the National Health
and Nutrition Examination Survey (NHANES). It is a major program
of the Center for Disease Control and Prevention (CDC), and its aim
is to assess the health and nutritional status of adults and children
in the USA. NHANES includes demographics, dietary habits, health-
related questions, and results of laboratory tests. These datasets
are available at http://www.cdc.gov/nchs/nhanes.htm.
Drug information was retrieved from the DrugBank database
[27]. Of the 6811 drug entities in the database, 1578 FDA-
approved drugs, and their 22,143 synonyms were included in our
research.
Literature information came from the biomedical literature
resources of PubMed. We downloaded and aggregated all publicly
available abstracts and Medical Subject Headings (MeSH) terms of
each published work, ranging from 1950 to 2011. We then
retrieved a total of 11,563,353 PubMed abstracts and their MeSH
information. Because MeSH terms indicate essential keyword
annotations of the literature, we utilized MeSH information in this
study.
The validation in this work used two independent datasets (CTD
[25] and Clinical Trials database [26]). A total of 469,609 chemical-
disease relationships manually curated from literature, and
197,234 studies that are currently under Clinical Trials were gath-
ered from the CTD and Clinical Trials database, respectively.
Fig. 1. A computational framework to infer new drug indications. Electronic clinical information (NHANES) and literature information are considered primary data sources.
From these data sources, two vectors showing clinical states are generated. The first is a clinical disease signature vector which consists of a set of clinical variables
representing significant changes between disease and healthy control in the electronic clinical data. The disease-related clinical variable and its relation directionality (‘‘up” or
‘‘down”) between disease and healthy control are obtained by statistical analysis (Wilcoxon rank sum test). The second vector is a clinical drug effect vector. It involves a set
of clinical variables that are associated with specific drugs, or small molecules, already in the published literature. Drug-associated clinical variables are identified by co-
occurrence-based literature mining. A list of drugs is from DrugBank, and abstracts and its keywords are obtained from PubMed. The association significance (p-value)
between a drug and a clinical variable in the PubMed abstracts and MeSH-information, was calculated by Fisher’s exact test. To extract the relation directionality between
drugs and clinical variables, we applied machine learning-based, literature-mining techniques to our study. In the end, final clinical disease signature and drug effect vectors
were established through a filter based on the MeSH information. Then, a score for each disease–drug pair was calculated by a comparison of the clinical disease signature and
drug effect vectors. These scores indicate the potential therapeutic effects of existing drugs.
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We collated health questionnaire and laboratory test results in
six cohorts from 1999 to 2010 in NHANES data. It contained 59,205
individual samples, 2369 clinical variables, 22 disease conditions.
Each sample size of all disease-conditions in the NHANES dataset
is represented in Table S1. Questionnaire information was used
to stratify individual samples into disease status (‘‘disease” or
‘‘control”). Individual samples who had been diagnosed with a cer-
tain disease-condition, defined as those answered ‘‘yes” submitted
on a questionnaire survey (e.g., ‘‘Doctor told you have asthma?”),
were grouped as the disease status. On the other hand, those
who answered ‘‘no” for all disease-conditions, were grouped as
the control. Next, to perform the statistical analysis for the identi-
fication of disease-related clinical variables (clinical disease signa-
tures), we filtered out clinical variables in laboratory test,
satisfying the following criteria.
(1) Each variable should be represented by a numerical value for
statistical analysis (Wilcoxon rank sum test).
(2) Variables should exhibit clinical meanings, for example, glu-
cose (LBXSGL) or triglyceride (LBXSTR).
(3) Variables should be expressed in consistent units of mea-
sure. For instance, although LBXSGL and LBDSGLIS both indi-
cate glucose concentration, these variables are expressed in
different units (mg/dL and mmol/L). In such cases, we chose
only one of the variables.
After filtering out clinical variables based on criteria above, a
total of 717 clinical variables were considered in this study
(Table S2).
Next, the sample size of disease-conditions is a critical factor to
ensure adequate power to detect statistical significance [28,29].Hence, we considered only disease-conditions in which the num-
ber of patients diagnosed with themwould be sufficient to perform
statistical analysis: type 2 diabetes, myocardial ischemia, stroke,
congestive heart failure and asthma. In this study, the sample size
of patients diagnosed with each disease-condition was greater
than 1000.
3. Methods
3.1. Problem statement
We took account of the problem of inferring alternative thera-
peutic indications of existing drugs by making use of electronic
clinical information. Our hypothesis was that a drug can have a
potential therapeutic effect on a disease if there are complemen-
tary relations between the clinical disease signature vector and
the clinical drug effect vector.
3.2. Clinical disease signature vector
In this study, we integrated six cohorts (1999–2000, 2001–
2002, 2003–2004, 2005–2006, 2007–2008, and 2009–2010) in
NHANES data; with five disease-conditions and 717 clinical vari-
ables. We constructed disease signature vectors (Table 1), which
contain the 717 clinical variables, for each of the five disease con-
ditions. Each clinical variable has the relation directionality that
indicates the direction of the significant value change between dis-
ease condition and healthy control. The relation directionality con-
sists of three relation types (‘‘up”, ‘‘down” and ‘‘no-relation”). The
‘‘up” or ‘‘down” relation type was assigned to a clinical variable,
when a clinical variable had a significantly increased or decreased
value over corresponding control values, and a relation type
of clinical variable with no significant value change was
Table 1
Statistics of clinical disease signature vectors: For each disease-condition, a clinical
disease signature vector was established. A clinical variable in the NHANES data was
defined as a significant clinical disease signature if it had a significantly higher or
lower measurement value than controls. The relation directionality (‘‘up”, ‘‘down” or
‘‘no-relation”) was obtained from a difference of the average rank for the clinical
variable between disease and healthy subgroups.
Disease Statistics of clinical disease signature vectors
Up
relations
Down
relations
No-
relations
Total
Type 2 diabetes 13 23 681 717
Myocardial ischemia 15 11 691 717
Stroke 13 15 689 717
Congestive heart
failure
13 17 687 717
Asthma 12 14 691 717
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‘‘down” relation type as clinical disease signatures. A list of clinical
disease signatures for each disease is represented in Table S3. The
significance of value change for each clinical variable was identified
using statistical analysis (Wilcoxon rank sum test). In this process,
we first applied the Wilcoxon rank sum test to the integrated
cohort to assign the p-value for each clinical variable. From the
calculated p-value for the Wilcoxon rank sum test, we further
estimated the false discovery rate (FDR) for the p-value to correct
for multiple testing, using the FDR (Benjamini-Hochberg) proce-
dure in SAS [30]. Although we could get the same results by using
a certain cut-off of p-value instead of using FDR, interpretations
between p-value and FDR are quite different. The FDR not only
has a clear, easily understandable meaning, but also give a far more
accurate indication of the level of false positives for the given cut-
off threshold. Therefore, we believed that FDR-based cut-off is
more reasonable than p-value-based cut-off in this study [31]. Only
clinical variables that satisfied the condition of FDR of less than 5%
could be clinical disease signatures. Next, the relation directional-
ity was assigned to the clinical variable by using a difference of the
average rank for the clinical variable between disease and control.3.3. Clinical drug effect vector
In this section, the generation of a clinical drug effect vector is
explained. As mentioned in the section on data sources, we col-
lected 11,563,353 abstracts published from 1950 to 2011 from
PubMed. We also retained 1578 FDA-approved drugs and 717 clin-
ical variables from the DrugBank database and NHANES data,
respectively (See Section 2). To reduce the search space in litera-
ture mining, we only used PubMed identifiers (PMIDs) containing
at least one drug–clinical variable pair used in this study, resulting
in 663,035 PMIDs.
Clinical drug effect vector contains the 717 clinical variables
with relation directionality between drugs and clinical variables,
which is same to the clinical disease signature vector. The relation
directionality in the clinical drug effect vector indicates drug
effects to clinical variables. For example, relation directionality is
‘‘up” if a drug increases the amount of a clinical variable, on the
other hand, it is ‘‘down” if a drug decreases the amount of a clinical
variable. When there is no effect between a drug and a clinical vari-
able, relation directionality is ‘‘no-relation”.
To establish clinical drug effect vectors, we first identified drug-
associated clinical variables by co-occurrence-based literature
mining that was widely used to discover meaningful associations
between two biological terms in simple manner [32]. The associa-
tion significance (p-value) between a drug and a clinical variable in
the PubMed abstracts and MeSH-information, was calculated by
Fisher’s exact test. The calculated p-values were then adjustedfor multiple testing by estimating the false discovery rate (FDR).
Only clinical variables with FDR values lower than 5% were allowed
to the next step.
For the remaining clinical variables, we determined the relation
directionality (‘‘up”, ‘‘down” and ‘‘no-relation”) of drug effects by a
supervised machine learning technique, specifically, the shallow
linguistic kernel suggested by 3.3 [33]. It is a good method to
extract a relation between entities from biomedical literature
based on shallow linguistic information, and its superior perfor-
mance was already verified in various entity-pairs [34,35].
The shallow linguistic kernel is defined as the linear combina-
tion of kernels, a global context kernel (GCL) and local context ker-
nel (LCK),
KSLðDi;CVjÞ ¼ KGCðDi;CVjÞ þ KLCðDi;CVjÞ
where Di and CVj indicate an example Drug(i)–Clinical variable(j)
pair.
A set of features of the global context kernel can be defined by
the following three patterns: Fore–Between, Between, and
Between–After, which are based on the Di–CVj pair (drug–clinical
variable) observations in the sentence. Therefore, it can be repre-
sented by a composite kernel defined for three patterns relative
to the detection of relations:
KGCðDi;CVjÞ ¼ KFore—BetweenðDi;CVjÞ þ KBetweenðDi;CVjÞ
þ KBetween—AfterðDi;CVjÞ
The local context kernel uses information about surface (punc-
tuation, capitalization, and numerals) and shallow linguistic (POS
tag, lemma, and stem) features derived from tokens to the left
and right partial sentence of the drug–clinical variable pair. Then,
it can be defined as the combination of left and right proper con-
text feature sets:
KLCðDi;CVjÞ ¼ K leftðDi;CVjÞ þ KrightðDi;CVjÞ
Since no corpus was available to generate the relation extrac-
tion models that classify the ‘‘up”, ‘‘down” or ‘‘no-relation” relation
directionality between a drug and a clinical variable, we manually
created the corpus that was specific for our research, resulting in
598 sentences annotated with 110 ‘‘up-relations”, 185 ‘‘down-
relations”, and 303 ‘‘no-relations”. In this process, we first selected
sentences that included three terms (drug, clinical variable and
pre-defined relational keyword). The relational keywords explain
the relation directionality between drugs and clinical variables,
and it was obtained from relation term in RelEx [36]. In the RelEx,
a list of relation terms is used to extract biological relations, such
as physical or regulatory interactions between genes and proteins
from free texts. Because all relation types in RelEx were not needed
in this step that identifies the ‘‘up” or ‘‘down” relation directional-
ity between drugs and clinical variables, we manually selected
‘‘up” and ‘‘down” relational keywords in accordance with our pur-
pose. Additionally, we added synonyms and word stems to extend
relational keywords using a large-scale lexical database of English,
i.e., WordNet [37]. Then, we obtained 65 ‘‘up” relation keywords
and 56 ‘‘down” relation keywords (Table S4), and they indicate
relation between two terms. Subsequently, for the selected sen-
tences, each relation type can be assigned by manual curation
(Fig. 2).
By using the created corpus, we generated relation extraction
models based on the shallow linguistic kernel for identifying the
‘‘up”, ‘‘down” and ‘‘no-relation” relation directionality between
drugs and clinical variables. These models then were evaluated
on the manually curated corpus using five-fold cross-validation
(Fig. S1). Next, we applied the generated model to 663,035 PubMed
abstracts containing at least one drug–clinical variable pair used in
Fig. 2. Assignment of relation type in the corpus generation: Three relation types (‘‘up”, ‘‘down” and ‘‘no-relation) are assigned to each sentence.
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pairs with ‘‘down” relation.
In the literature mining based relation extraction, there were
two particular cases. In the first case, conflicted relation direction-
ality between a drug and a clinical variable might be observed in
more than two sentences, although the drug and the clinical vari-
able were the same. For example, in the case of vidarabine (drug) –
lymphocyte (clinical variable) pair, the relation directionality was
extracted as ‘‘up” relation in three sentences, and ‘‘down” relation
in four sentences. In a case of conflicting result, the relation direc-
tionality between them can be determined in accordance with high
rates of the ‘‘up” relation and ‘‘down” relation. In other words, we
assigned the relation directionality to the drug–clinical variable
pair when the percentage of either ‘‘up” or ‘‘down” relation direc-
tionality with respect to the drug–clinical variable pair was over
70%, otherwise, the relation directionality was ‘‘no-relation”. After
this step, we finally obtained 1081 pairs with ‘‘up” relation and
2965 pairs with ‘‘down” relation.
In the second case, we could not extract the relation directional-
ity between drug and clinical variable because there was no rela-
tional keyword between them in a sentence. It would cause
information loss if we ignore significant drug–clinical variable pairs
(FDR < 5% by Fisher’s exact test) in the co-occurrence-based litera-
ture mining. Therefore, we assigned the relation directionality of
these significant drug–clinical variable pairs as ‘‘association” in
the clinical drug effect vector. Finally, taken together, the relation
directionality in the clinical drug effect vector contains four relation
types such as ‘‘up”, ‘‘down”, ‘‘association” and ‘‘no-relation”.3.4. Scoring function
For each disease–drug pair, we calculated a score that indicated
the potential therapeutic effect of the existing drug on a particular
disease. Our underlying hypothesis was that a drug can be reposi-
tioned on the disease-of-interest if there are complementary rela-
tions between the clinical disease signature vectors and clinical
drug effect vectors. Therefore, to obtain scores for disease–drug
pairs, we took into account complementarity with respect to the
relation directionality of clinical variables between a certain disease
andadrugof interest. Additionally, for significant drug–clinical vari-
able pairswith ‘‘association” relationdirectionality (See Section3.3),
we also considered the association of clinical variables between a
disease andadrug. Thus, our scoring function for a disease–drugpair
reflected the two conditions above and is represented by:
ScoreDisease—Drug ¼ aC CVDisease;CVDrug
 þ ð1 aÞA CVDisease;CVDrug
 
ð1Þ
Here, CðCVDisease; CVDrugÞ and AðCVDisease;CVDrugÞ are the ‘‘complemen-
tarity” and ‘‘association” scores between the clinical disease signa-
ture vector and the clinical drug effect vector, respectively. Thevalue of C is estimated by counting the number of clinical variables
having a complementary relation between a disease and a drug. It
can be calculated when the clinical variable has ‘‘up” or ‘‘down”
relation directionality in both clinical disease signature and drug
effect vector. In calculating A, the score of A is calculated by count-
ing the number of clinical variables that are with ‘‘up” or ‘‘down”
relation directionality in the clinical disease signature vector and
‘‘association” relation directionality in the clinical drug effect vec-
tor. Here, ‘a’ is a relative weighting factor between the complemen-
tarity and association score. In this study, we set the weighting
factor as ‘0.7’ because it achieved the best performance among
the candidate weighting factors to 0.1, 0.3, 0.5, 0.7 and 0.9
(Fig. S2). Fig. 3 illustrates an example of the scoring function.
3.5. Construction of gold-standard datasets
In this section, we explain the procedures for constructing gold-
standard datasets. The gold-standard dataset of disease–drug rela-
tionships was generated from two independent validation data-
sets: the Comparative Toxicogenomics Database (CTD) by the
Mount Desert Island Biological Lab in USA [25] and the Clinical Tri-
als [26] database, which comprises the results of clinical studies
conducted with human participants around the world. As a first
step to constructing a gold-standard dataset, we mapped chemical
IDs in the CTD to DrugBank IDs, resulting in 1042 mapped drugs
out of 1578 FDA-approved drugs in the DrugBank. We then
extracted relationships between these 1042 mapped drugs and
the five diseases used in this analysis from the CTD. In this step,
we only considered curated annotations with direct evidence set
to ‘‘therapeutic”. Consequently, we constructed the gold-standard
dataset, which included 358 between relationships 1042 mapped
drugs, and five diseases. Additionally, we obtained all disease–drug
relationships that were found to be either completed or undergo-
ing Clinical Trials from the official website of Clinical Trials
(http://clinicaltrials.gov/). We subsequently mapped drug names
to the DrugBank identifiers, resulting in 59,495 unique disease–
drug relationships that are undergoing Clinical Trials. Of these rela-
tionships, 447 relationships contained the diseases and drugs that
were considered in our study.
4. Results and discussion
4.1. Validation of disease–drug relationships against independent
datasets
Validation of the predictions was performed for each five dis-
ease case that had an enough sample size for a statistical test
because sample size influences prediction performance (Fig. S3).
To check whether our drug repositioning scores are valid or not,
we performed the fold-enrichment (FE) test for five disease
conditions by using known disease–drug relationships from the
Fig. 3. Concept of the scoring function: The score for a disease–drug pair is calculated by considering both ‘‘complementarity” and ‘‘association” between clinical disease
signature vectors and clinical drug effect vector. In this example, the disease and drug are connected via 717 clinical variables. Of these, CV1 and CV2 have complementary
relations between a disease and a drug, and CVn1 and CVn indicates the significant association between a disease and a drug without relational information. We used a = 0.7
in this study.
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evaluate the correlation between the score of a disease–drug pair
and the likelihood that a disease–drug relationship occurs. In the
FE test, all disease–drug pairs were ranked by the score and binned
into groups of 50 disease–drug pairs and Fold-Enrichment (FE)
score was defined as:
Fold-Enrichment ðFEÞ Score ¼ ðn=mÞðN=MÞ ð2Þ
where M, N are the number of all mapped drugs (1042) and the
number of drugs in response to each disease condition in the
gold-standard dataset, respectively. The number of drugs involved
in the gold-standard datasets within the group is n, and the number
of total drugs in the groups is m. In this study, we defined m as 50. If
our scoring function is reasonable, The FE score of a group having
high average disease–drug scores is higher than the group with
low average disease–drug scores. As shown in the Fig. S4, there
was a highly significant correlation between the average disease–
drug scores and FE scores.
Although the FE test is an indirect measure to capture the cor-
relation between disease–drug scores and therapeutic effects, it
may be reasonable for the disease–drug score to indicate the drug’s
potential to be a treatment for a certain disease. We also explored
the relative separation between verified and unverified disease–
drug relationships in the score distribution. By this way, we bench-
marked our predictions against known disease–drug relationships
derived from each validation dataset (CTD and Clinical Trials). As
shown in Fig. 4, disease–drug relationships verified in the valida-
tion datasets have higher scores than other unverified disease–
drug relationships.
In addition to that, the quantitative performance of the pro-
posed method was examined for each disease condition, and the
area-under-the-curve (AUC) scores of receiver-operating-character
istic (ROC) curve was used for assessment (Fig. S5).
To prune predicted relationships between diseases and drugs,
we generated a set of putative drug candidates in which only sig-
nificant (p < 0.05) drug candidates were considered to reduce false
discoveries (Table S5). We measured the significance (p-value) of
disease–drug scores by creating a background distribution of dis-
ease–drug scores calculated by randomly choosing the relation
directionality of clinical variables in clinical disease signature vec-
tors and clinical drug effect vectors. This task was repeated 10,000
times. Then, lists of candidate drugs with respect to each disease-
condition were generated, and all drugs in each list were ranked by
the inferred score. We then checked whether inferred disease–drug
relationships with significant scores statistically overlapped dis-
ease–drug relationships in verified validation datasets using a
hyper-geometric test. For every disease-condition, we found thatcoverage of two validation datasets in our significant prediction
results was markedly high (Table 2).
Additionally, we carried out a permutation test to verify that
the relationships between diseases and drugs found by our method
are more significant than randomly selected relationships. The sta-
tistical significance (p-value) of each disease–drug relationship in
the permutation test was estimated by counting how many of
the matched disease–drug relationships verified in validation data-
sets by randomly selected relationships (repeatedly generated
100,000 times) were larger than or equal to those predicted by
our method [38]. The test results were also statistically significant
for all disease-conditions (Table 2). Table 2 contains the results of
two significant tests for novel predictions. It shows that our model
predicted more meaningful disease–drug relationships than those
expected by chance.4.2. Literature analysis of inferred disease–drug relationships
In this section, we analyzed disease–drug relationships with
high scores to verify whether high-scored disease–drug relation-
ships are truly meaningful or not. We carefully examined associa-
tions between diseases and drugs by making use of clinical
variables and its relation directionality shared in clinical disease
signature and clinical drug effect vectors. Table 3 presents three
drug candidates, except for already known treatments to target
diseases, which are likely to be treatments for each disease-
condition. For each disease-condition, we selected the three drugs
that have reliable literature evidences, and were ranked in less
than 15th. Information about the relation directionality between
drugs and clinical variable are represented in Table S3, and a list
of all drug candidates containing already known drugs to target
diseases is supported in Table S5. Additionally, the information
about primary indications corresponding to candidate drugs is pro-
vided in Table S6.
An interesting finding is that several drugs (glutathione and
edetic-acid) related to anti-oxidants were identified as possible
treatments for asthma. One possible explanation is that oxidative
stress from the altered glutathione redox status may play a crucial
role in the pathogenesis and modulation of asthma [39,40]. Fitz-
patrick et al. insisted that glutathione may provide positive thera-
peutic opportunities for treating asthma patients whose airway
glutathione reserves are depleted [39]. Surprisingly, it is analogous
to the therapeutic effect (anti-inflammatory) of zinc (DB01593)
that is already known as a treatment for asthma [41]. Generally,
the anti-oxidants tends to have a natural anti-inflammatory action
without side-effects [42]. Additionally, in the clinical disease signa-
tures for asthma (see Table S3), the relation directionality of cobalt
(URXUCO) was identified as ‘‘up”. According to Pratviel et al., the
Fig. 4. Results of enrichment verification test: The log-scaled score distributions show the relative separation between verified (blue) and unverified (red) disease–drug
relationships in the validation datasets (CTD and Clinical Trials). In this plot, the verified disease–drug pairs are significantly enriched in higher scores than lower scores. The
range of original scores is from 0 (min) to 6.7 (max). In the log-scale transformation with respect to scores, the zero of a score is converted into minus infinity. Because the
minis infinity could not be represented in the graph, ‘‘0” was approximated to the small enough value (‘‘1E05”) in this work. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
Table 2
Results of significant tests for two independent datasets.
Disease # of drug candidates (p < 0.05) Coverage (%) Significance (p-value)
Hyper-geometric Permutation
CTD Clinical Trials CTD Clinical Trials CTD Clinical Trials
Type 2 diabetes 121 50.0 22.4 <0.001 <0.001 <0.001 <0.001
Myocardial ischemia 85 16.7 20.0 0.005 0.009 0.001 0.001
Stroke 102 21.8 22.0 <0.001 <0.001 <0.001 <0.001
Congestive heart failure 118 19.2 36.6 <0.001 <0.001 <0.001 <0.001
Asthma 36 15.6 7.31 <0.001 0.009 <0.001 0.001
Table 3
High-scored disease–drug relationships (among top 15 drugs). For each drug candidate, a score was calculated. The biological rationales of drug candidates with high scores were
studied in more detail using underlying literature.
Target disease Drug name (DrugBank ID) Rank Score p-value Structure similaritya Literature evidence (PMID)
Asthma Glutathione (DB00143) 1 5.1 0.0015 0.292 22304503
Edetic Acid (DB00974) 4 4.5 0.0036 0.383 23795964
22354928
Lithium (DB001356) 9 3.2 0.019 0 22210340
10531623
2427148
Type 2 diabetes Nitric Oxide (DB00435) 8 5.0 0.0019 0.048 –
Cyanocobalamin (DB00115) 11 4.8 0.0023 0.649 14066545
Penicillamine (DB00859) 14 4.5 0.0036 – 9837698
18688079
2645123
Congestive heart failure Creatine (DB00148) 4 5.4 0.001 – 22525652
12538418
Serum albumin (DB00096) 6 5.1 0.0015 0.622 25643435
Vitamin A (DB00162) 15 4.5 0.0036 – –
Myocardial ischemia Acetylcysteine (DB06151) 1 5.3 0.0013 0.386 10615413
3366508
11985902
Vitamin C (DB00126) 3 4.8 0.0023 – 24792921
19674720
Aluminum (DB01370) 4 4.3 0.0049 0 22306920
Stroke Cyclosporine-A (DB00091) 1 5.4 0.001 – 23277881
8050549
Penicillamine (DB00859) 5 4.9 0.0022 – –
Prednisone (DB00635) 7 4.7 0.0028 0.878 1556999
a The structure similarity to known treatments was represented by the Tanimoto-coefficient.
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level of the oxidative stress by the redox cycle catalyzing produc-
tion of reactive radicals and reactive oxygen species [43]. In the
case of lithium (DB001356), it had ‘‘down” of relation directionality
with respect to cobalt in the clinical drug effect vector. Moreover,
lithium had a negative effect to the level of barium (URXUBA). It
may reduce the contraction of smooth muscle in the airway [44],
which is one of the typical symptoms for asthma [45]. It seems
possible that lithium may be a candidate treatment for asthma.
We also found that penicillamine (DB00859) may be a potential
treatment for type 2 diabetes (T2D). Penicillamine is used for a
treatment of rheumatoid arthritis as a form of immunosuppression
[46]. Several studies reported that penicillamine can maintain the
concentration of insulin by producing autoantibodies to the insu-
lin, called insulin antibody reaction [47,48]. Although it may be
induce a side-effect (hypoglycemia) on non-T2D patients, it is pos-
sible that the penicillamine may be used for a treatment for T2D by
preventing the insulin clearance [48]. In addition to that, patients
with T2D had significantly higher level of albumin (URXUMA)
compared to healthy individuals [49]. It is consistent to the clinical
disease signatures for T2D by our method (see Table S3). According
to Alp et al., this result may be explained by the fact that albumin is
significantly associated with the insulin-inhibitory activity. In the
clinical drug effect vector, penicillamine had ‘‘down” of relation
directionality for albumin. Interestingly, the relation directionality
of albumin in telmisartan (DB00966) that is already used to treat
type 2 diabetes by improving insulin sensitivity is also ‘‘down”
[50]. Therefore, it is likely to be an evidence for a new use of the
penicillamine in T2D.
Other interesting finding is that creatine (DB00148) may be
used for a candidate treatment of congestive heart failure (CHF).
A possible explanation for this might be that creatine have an
effect to increase the red blood cells (RBC or hematocrit) [51]
and this result is in line with those of the clinical drug effect vector.
Generally, patients with CHF may have a related problem of ane-
mia. A decrease in the hematocrit may cause the anemia by limit-
ing the amount of oxygen being carried to the body, which makes
the heart work harder [52]. A low level of hematocrit (LBXHCT)
was also detected in the clinical disease signatures for CHF as men-
tioned in the previous work, and Karolczak et al. reported that one
drug of existing treatments of CHF (aspirin, DB00945) decrease the
level of hematocrit [53]. These factors may explain that creatine
may mitigate congestive heart failure.
In the case of myocardial ischemia, ischemic-reperfusion injury
is a primary symptom. The propensity to injure the myocardium
stems from the major responses of myocardium to proinflamma-
tory mediator. It can lead to a redirection of the normal inflamma-
tory response that neutralizes host invaders to one that attacks the
host tissues [54]. In this process, neutrophils (LBXNEPCT) plays a
role to attack host tissues [55]. Therefore, altering the activation
of neutrophils is one of the pharmacological therapies in myocar-
dial ischemia. It is consistent with an effect of original treatment
(irbesartan, DB01029) for myocardial ischemia, which reduce the
number of neutrophils in the body [56]. Acetylcysteine (known
as N-acetylcysteine or NAC, DB06151) is a major mucolytic agent
mitigating symptoms for a variety of pulmonary diseases [57]. In
our results, each relation directionality of neutrophils for the dis-
ease (myocardial ischemia) and the drug (NAC) was identified as
‘‘up” and ‘‘down”, respectively. Moreover, Sochman et al. also
reported that NAC has an effect to inhibit neutrophils [58]. It is
possible, therefore, that NAC may be used for the ischemic-
reperfusion injury mediator.
Cyclosporine-A (DB00091) is known as the treatment of trans-
plant rejection and rheumatoid arthritis. According to Osman
et al., Cyclosporine-A can act as a neuroprotective agent against
stroke and possesses neuroprotective properties through its abilityto block the mitochondrial permeability transition pore (MPTP),
which in turn inhibits neuronal damage [59]. It is a same role of
an existing drugs to treat stroke (hydrocortisone, DB00741) that
is also acting as the neuroprotective agent [60]. In the clinical dis-
ease signatures for stroke, (see Table S3), the relation directionality
of eosinophils (LBXEOPCT) was assigned as ‘‘up”. This results were
supported by previous studies that considered the high level of
eosinophils (called eosinophilia) as the cause of stroke [61,62]. In
the clinical drug effect vector, Cyclosporine-A had a negative effect
on eosinophils (‘‘down”). It is consistent to results of published
papers that explained the inhibitory effect of Cyclosporine-A on
eosinophils [63,64]. Therefore, it seems possible to be repositioned
as a treatment for stroke.
This analysis based on clinical variables may provide opportuni-
ties for discovering new therapeutic candidates of existing drugs
on the phenotypic level. Particularly, in this analysis, we compre-
hensively considered 717 clinical variables from electronic clinical
information (NHANES) that characterized the diseases and drugs.
With a set of clinical variables and its relation directionality, it
may allow phenotypic-level interpretations for indirect relation-
ships between diseases and drugs.
Furthermore, except for already known treatments for target
diseases, we could realize that most drug candidates are struc-
turally dissimilar to other approved-drugs known as treatments
for five diseases (low Tanimoto-coefficient). It is noteworthy that
the inferred drug candidates shown in Table 3 would not have been
predicted as new treatments for target diseases by the previous
chemical structure-based approach. Hence, these example shows
that electronic clinical information used in the proposed method
functions as feasible and effective data resources for drug reposi-
tioning research.
4.3. Limitations and further work
In our ongoing research, developing a computational frame-
work to identify new drug indications using the complementarity
between clinical disease signatures and drug effects, may provide
biomedical researchers with new insights. However, to archive fur-
ther improvements, there are some issues to be addressed.
A first limitation of the proposed method is the number of
disease-conditions considered in our research. In general statistical
analysis, a large sample size should be used to achieve better sta-
tistical power to detect important and precise effects or associa-
tions. Our results show a positive correlation between sample
size and prediction performance (Fig. S3). For this reason, we con-
sidered five disease-conditions for which include more than 1000
samples were available, although the NHANES dataset contains
information pertaining to other disease-conditions. The NHANES
program examines about 5000 persons per year to check their
health and nutritional status. This means that the number of
patients diagnosed with a certain disease is insufficient compared
to EHRs in hospitals. Therefore, we expect that the sample size
problem seems likely to be resolved by using plenty of clinical data
provided by hospitals.
A second limitation is using the literature mining technique to
link drugs and clinical variables. A common drawback of all litera-
ture mining-based approaches is that the information to be
extracted is dependent on the amount of biomedical studies
focused on something of our interests. For example, more biomed-
ical knowledge is available in well studied drugs than those in
poorly studied drugs in the PubMed abstracts. One of the solutions
to overcome this problem is extracting significant clinical variables
and its relation directionalities corresponding to drugs being eval-
uated from the Electronic Health Records (EHRs) provided by hos-
pitals. Unfortunately, those have been restricted to outsiders due
to privacy issues, and were not included in the publically available
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and Epidemiology Study (KoGES) [65]. For this reason, in our cur-
rent study, such information about drugs was identified by litera-
ture mining, even though it might contain the information loss
with respect to less studied drugs. However, it also seems likely
to be addressed by collaborating care-providing institutions.
The other limitation is differences between electronic clinical
information (NHANES or KoGES) and EHRs. Although electronic
clinical information is technically an electronic record of patient
health features, typically EHRs refer to operational clinical records
data from a care providing institution. To apply the EHRs to pro-
posed method, several points should be considered. In EHRs, since
laboratory tests for patients are not performed continuously, (i)
clinical values for patients may be incomplete and biased, and
(ii) it may be hard to identify pure health controls. Therefore, the
suggested method needs some modifications to be adapted to
EHRs, e.g., suitable data transform and missing value imputation
techniques to address the first consideration, and using records
in health medical examinations for healthy people to cope with
the second consideration. Based on the considerations and modifi-
cations above, we will adapt our method to the de-identified EHR
such as MIMIC-II [66]. It may allow us to analyze various
disease-conditions that are not handled due to small sample sizes
in this study.
Furthermore, to improve the performance of our method, we
need to combine clinical information with various data resources
including structural information about drugs, target-proteins,
side-effects information, and molecular activities. Particularly, In
the case of cancer, The Cancer Genome Atlas (TCGA) tried to pro-
vide not only clinical variables but also molecular profiles (DNA,
RNA and Epigenetics) of cancer patients [67]. It would be an inter-
esting further study to investigate relationships between diseases
and drugs by making use of multiple data resources.5. Conclusion
In this paper, we established a computational framework to
predict novel applications of existing drugs using electronic clinical
information which reflects the end-point physiological results of
drug impacts on the biological activities of humans. In this study,
we adopted the concept of complementarity between clinical dis-
ease signatures and clinical drug effects. Using the suggested com-
putational framework, we calculated a score for each disease–drug
relationship, indicating the repositioning potential of the respec-
tive drug toward the target disease. We showed the feasibility of
our proposed framework through statistical experiments (enrich-
ment verification, hyper-geometric, and permutation test). It
makes the suggested method useful to extract novel relationships
between diseases and drugs that have a high probability of being
biologically valid.Conflict of interest
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